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Effect of indomethacin and adrenocorticotrophic hormone on
renal function in man: An experimental model of inappropriate
antidiuresis. The effect of prostaglandin synthesis inhibition on
basal and ACTH-stimulated adrenal and renal function was in-
vestigated in normai volunteers. Data were collected during con-
trol and experimental study periods (13 days each). Adrenocorti-
cotrophic hormone (Cosyntropin, 80 U/day) was administered
i.v. on days 8 and 9 of each period. Indomethacin (150 mg/day)
was given on days 5 through 13 of the experimental period. The
subjects ate a constant diet containing 9 mEq of sodium, 100
mEq of potassium, and 2,500 ml of fluid daily. Indomethacin
markedly inhibited urinary PGE excretion and plasma PGE con-
centration. The effect of ACTH alone as compared to the effect
of ACTH and indomethacin showed: plasma sodium concentra-
tion, 139 I vs. 131 3 mEg/liter (P < 0.01, mean sEM);
plasma osmolality, 287 3 vs. 270 3 mOsm/liter (P < 0.01);
free water clearance, 97 66 vs. —1100 380 ml/24hr (P <
0.01); urine volume, 2,000 60 vs. 950 200 mllday (P <0.01);
and urine osmolality 282 12 vs. 720 144 mOsm/liter (P <
0.01). We conclude that the effects of ACTH and prostaglandin
synthesis inhibition interact to result in inappropriate anti-
diuresis.
Effet de l'indométhacine et de l'hormone adrénocorticotrope sur
Ia fonction rénale chez l'homme: Un modèle experimental
d'antidiurèse inappropriée. L'effet de l'inhibition de la synthese
de prostaglandine sur Ia fonction surrénalienne basale et stimu-
lee par I'ACTH et sur la fonction rdnale a été étudié chez des
sujets normaux volontaires. Les résultats ont été obtenus au
cours de periodes contrôles et expérimentales de 13 jours cha-
cune. De l'hormone adrenocorticotrope (Cosyntropin) a été ad-
ministrée par voie iv. les 8ème et 9ème jours de chaque période
a raison de 80 U par jour. L'indométhacine, 150 mg/jour, a été
donnée du 8ème au l3ème jour de Ia pénode expérimentale. Les
sujets ont été soumis a un régime constant contenant 9 mEq de
sodium, 100 mEq de potassium, et 2,500 ml de liquide par jour.
L'indométhacine a fortement inhibé l'excrétion urinaire de PGE
et abaissé Ia concentration plasmatique de PGE. L'effet de
l'ACTH seul compare a l'effet de l'ACTH associé a l'indomé-
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thacine a montré: une concentration plasmatique de sodium
de 139 I vs. 131 3 mEq/litre (P < 0,01) moyenne et sEM);
une osmolalité plasmatique de 287 3 vs. 270 3 mOsm/litre
(P < 0,01); une clearance de l'eau libre de 97 66 vs. — 1100
380 ml/24 hr (P <0,01); un debit urinaire de 2,000 60 vs. 950
200 mI/jour (P < 0,01); et une osmolalitd urinaire de 282 12
vs. 720 144 mOsm/litre (P < 0,01). Nous considérons que les
effets de l'ACTH et de l'inhibition de Ia synthese de prosta-
glandine se combinent pour determiner une antidiurése in-
appropriée.
The maintenance of cellular, interstitial, and ex-
tracellular fluid isotonicity is dependent upon the in-
tegrated functions of the hypothalamus, pituitary,
and kidney [1-611. The molecular mechanism of ac-
tion of vasopressin in the regulation of water per-
meability of epithelial membranes has been eluci-
dated through numerous studies with the toad uri-
nary bladder [7]. Vasopressin has been shown to
activate adenylate cyclase, resulting in the accumu-
lation of cyclic adenosine 3',5'-monophosphate (cy-
clic AMP) [8]. This increase in cellular cyclic AMP
concentration results in an increase in the water
permeability of the epithelial surface of the toad uri-
nary bladder [9] and the mammalian renal collecting
duct [10]. Exogenously administered cyclic AMP or
theophylline, a cyclic nucleotide phosphodiesterase
inhibitor, mimics the effects of antidiuretic hormone
(ADH) in increasing the water permeability of the
toad urinary bladder [9] and rabbit collecting duct in
vitro [10].
Prostaglandins of the E series (PGE) are potent
inhibitors of vasopressin-stimulated water per-
meability in the toad urinary bladder [11, 12] and
rabbit collecting duct in vitro [13]. Furthermore,
inhibitors of prostaglandin biosynthesis enhance the
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water permeability response of these tissues [14].
These observations led Grantham and Orloff [131 to
suggest that PGE was an in vivo modulator of ADH
activity. Recent studies have revealed that vaso-
pressin is a potent stimulant of PGE2 biosynthesis in
rabbit renomedullary interstitial cells in tissue cul-
ture [15, 161, in the rat [17, 18], and in the rabbit
[19]. These studies suggested that the stimulation of
PGE2 biosynthesis by ADH in vivo might inhibit
vasopressin-stimulated water permeability. Zus-
man, Keiser, and Handler demonstrated that in the
toad urinary bladder in vitro arginine vasopressin is
a potent stimulant of PGE biosynthesis [20]. Vaso-
pressin-stimulated PGE biosynthesis by the urinary
bladder inhibits vasopressin-stimulated water per-
meability. Mepacrine, a phospholipase inhibitor;
the nonsteroidal antiinflammatory agents, such as
indomethacin, naproxen, ibuprofen, and meclofen-
amate; and the sulfonylureas, such as chlorpropa-
mide, tolbutamide, and glyburide inhibit vasopres-
sin-stimulated PGE biosynthesis and, as a con-
sequence, enhance vasopressin-stimulated water
permeability [20, 21].
Adrenal steroid hormones also enhance vaso-
pressin-stimulated water flow in the toad urinary
bladder [22]. This effect was thought to be caused
by the steroids' inhibition of cyclic nucleotide phos-
phodiesterase, with a resultant increase in cyclic
AMP accumulation [23]. Zusman, Keiser, and
Handler [24] have shown that adrenal steroid hor-
mones are potent inhibitors of PGE biosynthesis in
the toad urinary bladder. Thus, the enhancement of
vasopressin-stimulated water flow by adrenal ste-
roid hormones in the toad bladder is caused by the
inhibition of cyclic nucleotide phosphodiesterase as
well as the inhibition of PGE biosynthesis.
The purpose of this investigation was to deter-
mine the effects of prostaglandin synthesis inhibi-
tion and the administration of adrenocorticotrophic
hormone (ACTH) on adrenal and renal function.
Methods
Study protocol. Fourteen normal volunteers (2
men and 12 women), aged 19 to 23 years old (mean
age, 21 years), were studied as inpatients of the Na-
tional Heart, Lung, and Blood Institute. Each vol-
unteer underwent complete physical examination,
chest radiograph, electrocardiogram, and laboratory
screening tests prior to the study. None of the sub-
jects took any medications in the 2 weeks before the
beginning of the protocol nor did they take any
medications other than those associated with the in-
vestigation during the study. The protocol for the
study was approved by the NIH Clinical Research
Committee, and all subjects gave informed consent
in writing.
Data were collected during the control and exper-
imental periods. The duration of each period was 13
days; the periods were separated by 14 days. Dur-
ing each study period, the subjects adhered to a
constant diet containing 9 mEq of sodium and 100
mEq of potassium per day. Each subject drank
2,500 ml of fluid daily, with the exception of the
days on which ACTH was administered, when
1,500 ml was given orally and 1,000 ml was given
i.v. On days 8 and 9 of each period, Cosyntropin, 80
U/day (noon to noon), was given i.v. in a total vol-
ume of 1,000 ml of 5% dextrose in water. During the
experimental period, indomethacin (50 mg per os,
three times per day, with meals) was given on days
5 through 13.
Daily (noon to noon) urine samples were collect-
ed. Venous blood samples were obtained for mea-
surement of sodium, potassium, osmolality, and
creatinine. Plasma cortisol levels were determined
before and during the ACTH infusion at 4 P.M. and
9 A.M. Venous blood samples for determining PGE
and plasma renin activity were obtained before
and during the ACTH infusion between 8 A.M.
and 9 A.M. with the subject in the supine position,
and between 11 A.M. and noon after 3 hours in the
upright position. Urinary and plasma sodium, po-
tassium, osmolality, and creatinine were measured
by the National Institutes of Health Clinical Labora-
tories. Plasma cortisol, and urinary 17-hydroxy and
17-keto-steroids were measured by Bio-Science
Laboratories. Plasma renin activity, and the con-
centrations of plasma renin, plasma renin substrate,
and urinary aldosterone were measured by Hazel-
ton Laboratories (Rockville, Maryland) under a
special contract with the National Heart, Lung, and
Blood Institute. Plasma PGE was measured by ra-
dioimmunoassay [25, 26]. Urinary PGE excretion
was measured by radioimmunoassay, as previously
described [27].
Statistical analysis. The control value for all mea-
surements was the mean of the three observations
on days 5, 6, and 7 of the control period. During the
control period, values for days 8 through 13 were
compared with control values to assess the effect of
ACTH administration by Student's t test for paired
observations [28]. During the experimental period,
statistical comparison was made with the cone-
sponding day of the control period to assess the ef-
fect of prostaglandin synthesis inhibition by Stu-
dent's t test for paired observations [281.
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Results
Effect of indomethacin on plasma PGE concen-
tration and urinary PGE excretion (Fig. 1, Table 1).
The plasma PGE concentration was 149 10 pg/mi
(mean SEM) with subjects in the supine position
and was unaffected by the upright position or by
ACTH administration. Control urinary PGE excre-
tion was 35.2 4.1 ng/hr, and was unaffected by
ACTH administration.
During indomethacin administration, the plasma
PGE concentration fell to 22 3 pg/mi in the supine
position and was unaffected by the upright position
or by ACTH administration. Plasma PGE levels
were significantly lower in the experimental than
they were in the control periods (P <0.001). During
indomethacin administration, urinary PGE excre-
tion fell to 74.2 10.5% of control value (P <0.05)
on day 5; for days 6 through 13, urinary PGE excre-
tion was 48.3 2.0% of control PGE excretion (P <
0.001).
Effect ofACTH and prostaglandin synthesis inhi-
bition on sodium, potassium, and water metabolism
(Figs. 2-5, Table 1). Plasma sodium concentration
was 139 1 mEq/liter throughout the control peri-
od. During the experimental period, plasma sodium
concentration was 140 1 mEq/liter before ACTH
administration, but fell to 131 3 mEq/liter after 48
hours of ACTH (P <0.01). Plasma sodium concen-
tration rose to 138 1 mEq/iiter 96 hours after the
ACTH infusion was completed.
Urinary sodium excretion was 3.9 1.1 mEq/li-
ter prior to ACTH administration during the control
and experimental periods. Sodium excretion fell to
1.1 0.4 and 0.3 0.2 mEq/24 hr on the first and
second days of ACTH administration (P < 0.01),
respectively, during the control and experimental
periods.
Plasma potassium concentration 4.0 0.1 mEqI
liter, was unaffected by ACTH, indomethacin, or a
combination of the two. Basal urinary potassium
excretion was 88.3 3.6 mEq/24 hr during the con-
trol study period. During the first day of ACTH in-
fusion, urinary potassium excretion rose to 131
9.4 mEq/24 hr (P < 0.001) but subsequently fell to
Table!. The effect of prostaglandin synthesis inhibition and adrenocorticotrophic hormone (ACTH) on renal function in normal man
Control perioda Experimental perioda
Basal ACTH Basal ACTH
Plasma sodium, mEqiliter 139 1 139 1 140 1 131 3
Plasma osniolality, mOsmiliter 287 3 287 3 283 2 270 3c
Urine volume, m1124 hr 2220 60 1999 78 1740 65 950 200e
Urine osmolality, mOsm/liter 250 16 282 12 259 17 720 144
Free water clearance, ml/24 hr 333 110 97 66" 201 90 1090 380
Aldosterone excretion rate, p.g/24 hr 62.5 7.4 192.4 263b 49•4 l.9 118.3 77e
PRA (supine), nglml/hr 3.3 0.5 5.0 0.7" 3.2 0.5 4.8 2.8
PRA (upright), ng/ml/hr 9.0 1.0 14.2 1.3" 6.9 l.2' 4.5 l.5'
PRS (supine), pg/mi 0.91 0.06 1.44 0.07" 0.95 0.07 1.25 0.14
PRS(upright),pg/ml 0.82 0.09 1.41 0.14" 1.02 0.13 1.50 0.17
PRC (supine), 1iU/ml 167 37 205 59 121 30 125 106
PRC (upright), p.UIml 485 119 691 157 156 45c 65 21c
a In the control and experimental periods, the "basal" value represents the mean of observations on days 5, 6, and 7 of each period.
The "ACTH" value represents the observation after 48 hours of ACTH infusion, with the exception of the aldosterone excretion rate,
which is the value observed after 24 hours of ACTH infusion.
b P <0.05 compared to "basal".
P < 0.05 compared to "control" period.
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Fig. 1. Effectof indomethacin on urinary prostagiandin E (PGE)
excretion during the experimental period. An asterisk (*) in-
dicates statistical significance (P < 0.05) compared to the equiva-
lent study day of the control period.
levels below control for 72 hours before returning to
control levels. During the experimental period, bas-
al potassium excretion, 75 3.1 mEqI24 hr, was
lower than that of the control period (P < 0.02).
During the first day of ACTH administration, potas-
sium excretion increased to 110.8 10.1 mEq/24
hr, which was greater than the basal potassium ex-
cretion for the experimental period (P < 0.01), but
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Fig. 2. Effect of adrenocorticotrophic hormone (ACTH) on urine
volume (V),free water clearance (Cff20), urine osmolality (U0,,,),
osmolar clearance (C0,,,), and weight. An asterisk (') indicates
statistical significance (P < 0.05) compared to the mean of the
values on days 5, 6, and 7.
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less than urinary potassium after ACTH administra-
tion during the control period (P < 0.01).
Plasma creatinine, 0.94 0.02 mg/100 ml, and
creatinine clearance, 145 2.0 liter/24 hr, were unaf-
fected by ACTH, indomethacin, or a combination
of the two.
Plasma osmolality was constant, 287 3 mOsm!
liter, during the control period and was unaffected
by the administration of indomethacin or ACTH.
After 48 hours of ACTH administration during the
experimental period, plasma osmolality fell to 270
3 mOsm/liter (P < 0.01).
Basal osmolar clearance was 1,780 50 ml/24 hr
during the control period. Osmolar clearance rose
to 2,210 100 ml/24 hr P < 0.001) and 1,910 70
m1124 hr (P < 0.05) on the first and second days of
ACTH administration, respectively. Basal osmolar
clearance and the increase in osmolar clearance af-
ter ACTH administration were unaffected by indo-
methacin.
Urine volume was 2,220 60 m1124 hr throughout
the control period; basal urine volume during the
experimental period was 1,740 65 m1124 hr and
was statistically lower (P < 0.01) than the basal
urine volume was during the control period. On the
first and second days of ACTH infusion, urine vol-
ume fell to 1,250 250 m1124 hr (P < 0.02) and 950
200 mI/24 hr (P < 0.01), respectively. A weight
gain of 1.5 0.3 kg/subject (P < 0.001) was associ-
ated with the marked fall in urine volume during
ACTH infusion.
During the control period, basal urine osmolality
was 250 16 mOsm/liter. During the ACTH in-
fusion, urine osmolality rose slightly to 282 12
mOsm/liter (P < 0.01). Basal urine osmolality dur-
ing the experimental period was 259 17 mOsm/
liter. In the experimental study period, urine os-
molality rose to 579 118 and 720 144 mOsm/
liter (P < 0.01) during the first and second days of
ACTH infusion, respectively. On the first day after
the termination of ACTH infusion, a diuresis was
observed during the experimental period. The urine
volume was 2,980 580 ml/24 hr (P <0.02) and the
urine osmolality was 190 47 mOsm/liter (P <
0.01).
Free water clearance during the control period
was333 llOmIJ24hr,andfellto97±66m1/24hr
(P < 0.02) on the second day of the ACTH infusion.
Fig. 4. Effect of adrenocorticotrophic hormone (ACTH) on
creatinine clearance (C,), urinary sodium excretion (UNV), uri-
nary potassium excretion (U5V), urinary 17-hydroxy-, and 17-
keto-steroids, aldosterone excretion rate (AER), and plasma re-
nm activity (PRA). An asterisk (*) indicates statistical signifi-
cance (P < 0.05) compared to the mean of values on days 5, 6,
and 7.
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Basal free water clearance during the experimental
period was 201 90 m1124 hr. During the ACTH in-
fusion in the experimental study period, the free
water clearance fell to —725 365 and —1,090
380 m1124 hr (P <0.01) during the first and second
days, respectively. On the day immediately follow-
ing termination of the ACTH infusion, free water
clearance rose to 1,310 480 m1124 hr (P < 0.02)
during the experimental period.
Effect of prostaglandin synthesis inhibition on
basal and ACTH-stimulated adrenal steroid-
ogenesis (Figs. 4 and 5, Table 1). Plasma cortisol
concentrations during the control period were 7.1
0.6 and 12.4 0.4 ng/100 ml at 4 P.M. and 9 A.M.,
respectively. During ACTH infusion, the plasma
cortisol levels rose to 45.2 3.5 and 47.7 4.0 ng/
100 ml at 4 P.M. and 9A.M., respectively. Basal uri-
nary 17-hydroxy-steroid excretion was 5.0 0.4
mg/24 hr. Urinary 17-hydroxy-steroid excretion in-
creased to 36.7 4.2 and 72.4 5.6 mg124 hr (P <
0.01) by the first and second days of ACTH in-
fusion, respectively. Basal urinary 17-keto-steroid
excretion, 14.5 0.9 mg124 hr, increased to 28.6
2.8 and 48.8 4.8 mg/24 hr (P < 0.001) during the
first and second days of ACTH infusion, respective-
ly. Basal and ACTH-stimulated plasma cortisol lev-
els and urinary 17-hydroxy and 17-keto-steroid ex-
cretion were unaffected by indomethacin.
Basal urinary aldosterone excretion was 62.5
7.4 g/24 hr. During ACTH infusion, aldosterone
excretion increased to 192.4 26.3 and 100.3
11.8 j.g/24 hr (P < 0.001) on the first and second
days of ACTH infusion, respectively. Basal al-
dosterone excretion during the experimental period
was 49.4 1.9 g/24 hr; this value was significantly
lower (P <0.02) than was the value obtained during
the control period. Aldosterone excretion on the
first and second days of the ACTH infusion in the
experimental period was 118.3 7.7 and 51.6 8.1
/Lg/24 hr, respectively. Aldosterone excretion was
significantly lower (P < 0.01) during the ACTH in-
fusion in the experimental period than it was in the
control period.
Effect of prostaglandin synthesis inhibition and
ACTH on plasma renin activity (Figs. 4 and 5 and
Table 1). Plasma renin activity (PRA) during the
Fig. 5. Effect of adrenocorticotrophic hormone (ACTH) and
prostaglandin synthesis inhibition with indomethacin, 150 mgI
day, on creatinine clearance (Cc,), urinary sodium excretion
(UNaV), urinary potassium excretion (UV), urinary 17-hydroxy-
and 17-keto-steroids, aldosterone excretion rate (AER), and
plasma renin activity (PRA). An asterisk (*) indicates statistical
significance (P < 0.05) compared to the equivalent study day of
the control period (shown in Fig. 4).
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control period was 3.3 0.5 and 9.0 1.0 nglmL'hr
with subjects in the supine and upright positions,
respectively. After 48 hours of ACTH infusion,
PRA increased to 5.0 0.7 (P < 0.02) and 14.2
1.3 ng/ml/hr (P < 0.001) in the supine and upright
positions, respectively. During the experimental pe-
riod, PRA was 3.2 0.5 and 6.0 1.2 ng!mllhr in
the supine and upright positions, respectively. The
basal "upright" PRA was lower (P < 0.01) during
the experimental than it was in the control period.
After ACTH infusion, PRA was 4.8 2.8 and 4.5
1.5 ng/mllhr in the supine and upright positions, re-
spectively; the "upright" PRA was lower (P <
0.005) during the experimental than it was during
the control period.
The increase in PRA during ACTH infusion was
secondary to an increase in the plasma renin sub-
strate concentration. Basal plasma renin substrate
(PRS) concentration was 0.91 0.06 and 0.82
0.09 g/ml in the supine and upright positions, re-
spectively. During ACTH administration, PRS con-
centration increased to 1.44 0.07, and 1.41 0.14
sg/ml (P < 0.001) in the supine and upright posi-
tions, respectively. Plasma renin substrate concen-
tration was unaffected by prostaglandin synthesis
inhibition during the basal or ACTH-infusion peri-
ods.
The fall in PRA during indomethacin administra-
tion was secondary to a fall in plasma renin concen-
tration [201. Basal plasma renin concentration
(PRC)was 167 37 and 485 119 /LU/ml (P <0.01)
in the supine and upright positions, respectively.
During the experimental study period, PRC was 121
30 and 156 45 /LU/ml in the supine and upright
positions, respectively. The PRC in the upright po-
sition was significantly lower than that in the con-
trol period (P < 0.01). The PRC was unaffected by
the ACTH infusion during the control or experi-
mental study periods. Indomethacin's effect on
plasma renin concentration but not on plasma renin
substrate is consistent with prior observations of
the role of prostaglandins in the regulation of
plasma renin activity [30—35].
Discussion
Although previous studies [36-42] have suggested
that PGE might mediate the stimulation of adrenal
steroidogenesis by ACTH, this study does not sup-
port the role of prostaglandins in basal or ACTH-
stimulated adrenal function. Although significant in-
hibition of plasma and urinary PGE levels was
achieved, no change occurred in basal or ACTH-
stimulated plasma cortisol, or in urinary 17-hy-
droxy- or 17-keto-steroid levels. The basal and
ACTH-stimulated urinary aldosterone excretion
rate fell during the indomethacin-treatment period.
Although this might reflect a selective role for the
prostaglandins in the regulation of aldosterone bio-
synthesis, the decrease in plasma renin activity that
was observed during the indomethacin administra-
tion is a more likely explanation for the fall in al-
dosterone excretion.
In contrast to the findings of other workers, we
found that prostaglandin synthesis inhibition had no
effect on plasma creatinine or creatinine excretion.
Previous studies had shown that prostaglandin syn-
thesis inhibition in patients with Bartter's syndrome
[27], rheumatoid arthritis [43], and systemic lupus
erythematosus [441 resulted in a fall in renal creati-
nine clearance. In each of these diseases, excretion
of urinary PGE-like material is abnormally high;
thus, renal blood flow may be dependent upon a
sustained elevation of renal prostaglandin biosyn-
thesis. Inhibition of prostaglandin biosynthesis has
not consistently altered renal function. Friedman et
al [451 and Donker et al [461 found that prostaglan-
din synthesis inhibitors decreased creatinine clear-
ance, whereas Burry and Dieppe [47] found that sa-
licylates had no effect on creatinine clearance. De-
spite a 50% reduction in urinary PGE excretion, no
change in creatinine clearance was observed in this
study.
In our study, indomethacin did not affect sodium
excretion in subjects on a diet of 9 mEq of sodium
per day. Indomethacin reduced potassium excre-
tion during the basal and ACTH periods as com-
pared with the control period. This decrease in po-
tassium excretion is consistent with observations
made in other studies [27].
The striking changes in water balance during
ACTH and indomethacin administration have not
been previously recorded. During simultaneous
ACTH and indomethacin administration, we ob-
served a marked fall in urinary volume and free wa-
ter clearance. Decreased plasma sodium concentra-
tion and plasma osmolality, increased urine os-
molality, and weight gain were all associated with
the fall in free water clearance. Prostaglandin E in-
hibits vasopressin-stimulated water flow by inhib-
iting vasopressin-stimulated accumulation of cyclic
3',S'-adenosine monophosphate [48]. Prostaglandin
synthesis inhibition is known to enhance vasopres-
sin-stimulated water flow in rat [49], dog [50], man
[51], and toad urinary bladder in vitro [14, 20, 21,
24]. In this study, inappropriate antidiuresis was ob-
served during the simultaneous administration of
Indomethacin, ACTH, and inappropriate antidiuresis 69
ACTH and indomethacin. The inappropriate anti-
diuretic phase was dependent on both the ACTH
and the indomethacin; as soon as the ACTH in-
fusion was discontinued, a prompt diuresis oc-
curred. Antidiuresis was observed in previous stud-
ies of the effect of ACTH on adrenal and renal func-
tion [52]. In those studies, a crude pituitary
preparation of ACTH was used; these pituitary
preparations were no doubt contaminated by ADH,
thus accounting for the antidiuretic activity ob-
served. We used Cosyntropin, a synthetic ACTH
polypeptide. This synthetic peptide has no homolo-
gous structure to ADH, and it has not been pre-
viously reported to possess antidiuretic activity.
We conclude that prostaglandin synthesis inhibi-
tion and the administration of ACTH result in in-
appropriate antidiuresis. The mechanism for the
stimulation of water reabsorption despite plasma
hypoosmolality and hyponatremia is not known, al-
though a number of possibilities should be consid-
ered. Robertson, Shelton, and Athar [3] have
shown that plasma vasopressin concentrations fall
to low but detectable levels in normal subjects de-
spite hypoosmolality. Prostaglandin synthesis inhi-
bition is known to enhance renal vasopressin action
in man [51]. Furthermore, adrenal steroid hormones
are known to enhance vasopressin-stimulated water
flow in the toad urinary bladder [22-24]. The effect
of steroid hormones on vasopressin-stimulated wa-
ter flow in the toad urinary bladder is due in part to
the inhibition of PGE biosynthesis [24] but is also
due to a decrease in phosphodiesterase activity
[23]. During the experimental period, adrenal ste-
roidogenesis was markedly increased, and PGE bio-
synthesis was decreased. These two factors could
potentially enhance the effectiveness of even low
concentrations of circulating vasopressin and,
therefore, result in inappropriate antidiuresis. Or,
inappropriate antidiuresis may occur because
ACTH and prostaglandin synthesis inhibition inter-
act to: (1) induce persistent release of antidiuretic
hormone from the pituitary, similar to the persistent
release of vasopressin observed in patients with ma-
lignancies, (2) result in a failure in osmoreceptor
function, or (3) result in the release or activation of
a substance, other than arginine vasopressin, with
antidiuretic hormone-like activity.
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